The Bordey Lab has been focused on the mammalian Target of Rapamycin, mTOR. mTOR is a converging point in cell signaling, or in other terms an intracellular hub, that receives signals from diverse intracellular routes and extracellular ligands. Importantly, mTOR is dysregulated in many neurological disorders. These disorders referred to as mTORopathies include (but are not limited to) Tuberous Sclerosis Complex (TSC), autism, Alzheimer’s disease, and Schizophrenia. We have focused on TSC. Dr. Angélique Bordey holds the rank of Professor of Neuroscience at the Yale School of Medicine.